JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

Anesth Analg 1983; 62:679-685
© 1983 International Anesthesia Research Society
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pandit, U. A.
Right arrow Articles by Pandit, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pandit, U. A.
Right arrow Articles by Pandit, S. K.

Physostigmine Fails to Reverse Clinical, Psychomotor, or EEG Effects of Lorazepam

Uma A. Pandit, MD, Sarla P. Kothary, MD, Satwant K. Samra, MD, Edward F. Domino, MD, and Sujit K. Pandit, MD

Departments of Anesthesiology and Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan.

Abstract

Physostigmine salicylate (2.0 mg) or 0.9% NaCl (2.0 ml) was administered intravenously in a double-blind fashion to adult volunteers in an attempt to reverse the effects of a 0.05-mg/kg dose of lorazepam given intravenously 30 min earlier. No other medication affecting the central nervous system was given. No differences were observed between the two groups with regard to the frequency of amnesia, psychomotor impairment, or EEG changes during a period of 4 h. The only significant difference in the level of sedation between the two groups was observed 60 min into the study. This difference is attributed to the high incidence of nausea and vomiting that occurred at that time exclusively in one group. Time to complete recovery was the same in both groups. However, physostigmine, not saline, was associated with a high incidence of muscarinic and sympathetic stimulating effects. The results obtained indicate that at the dose used, physostigmine is of no clinical value in treating sedation induced by lorazepam.

Key Words: HYPNOTICS, Benzodiazepines: lorazepam • ANTAGONISTS, Miscellaneous: physostigimine




This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
C. Gilles and R. Luthringer
Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs
J Psychopharmacol, May 1, 2007; 21(3): 272 - 282.
[Abstract] [PDF]

Home page
 Hum Exp ToxicolHome page
P. Lheureux and R. Askenasi
Specific Treatment of Benzodiazepine Overdose
Human and Experimental Toxicology, March 1, 1988; 7(2): 165 - 170.
[Abstract] [PDF]


Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press
Copyright © 1983 by the International Anesthesia Research Society.